MedMira报告说,2025年收入下降,损失增加,但获得了关键的监管批准以及先进的临床试验和AI诊断。 MedMira reported a revenue drop and larger loss in 2025, but achieved key regulatory approvals and advanced clinical trials and AI diagnostics.

MedMira公司报告说,2025财政年度的收入下降至240 509美元,比上一年的412 568美元增加,净损失450万美元,比330万美元增加,原因是研发和销售费用增加。 MedMira Inc. reported a revenue drop to $240,509 for fiscal year 2025, up from $412,568 the prior year, with a net loss of $4.5 million, up from $3.3 million, driven by higher R&D and sales expenses. 尽管面临财政挑战,该公司将总利润率提高到72%,并实现了加拿大对Multiplo TP/HIV和Reveal TP梅毒测试的主要监管批准,使各省得以推出。 Despite financial challenges, the company improved gross profit margin to 72% and achieved key regulatory approvals in Canada for its Multiplo® TP/HIV and Reveal® TP syphilis tests, enabling provincial rollout. 在美国,它获得了VA和联邦名单,扩大了获得政府合同的机会。 In the U.S., it secured VA and federal listings, expanding access to government contracts. Multiplo TP/nTP和自我测试版本的临床试验提前进行,预计于2025年12月初取得结果。 Clinical trials advanced for its Multiplo® TP/nTP and self-test versions, with results expected in early December 2025. 该公司还推进了AI-集成 MiROQ的快速定量测试诊断平台,目的是通过战略伙伴关系实现商业化。 The company also progressed its AI-integrated MiROQ diagnostic platform for rapid, quantitative testing, aiming for commercialization through a strategic partnership.